AACCE Investments
ScreenerStocksIndicesPicksETFsBlogPricing

© 2026 ACCE Investments. All rights reserved.

ACCE Investments - Institutional-grade stock research for retail investors | BetaList
IndicesStocksETFsScreenerBlogGlossaryCompareMarket dataAdvisors
TermsPrivacyCookiesDisclaimerLegal noticeProfessional termsAboutContact
CON

Concentra Group Holdings Parent Inc. Common Stock (CON) fair value

Healthcare · Medical Care Facilities · NYSE · United States
$39.25-1.80%
Market cap $5.0BNext earnings 2026-11-05Updated Oct 21, 2026
Add earnings to calendarGoogle
Our verdict
Trades 47% above our fair value
Price
$39.25
Model fair valueConfidence: good
$26.63
Model range
$19.05 to $40.45
Fair value $26.63
Price $39.25
3 models fit Concentra Group Holdings Parent Inc. Common Stock and they disagree: 0 of 3 land within 15% of the average.
Two or more of our models back this value.
Large premium(i)Bronze56
Valued as a mature, profitable company: Discounted cash flow, P/E comparison, EV/EBITDA comparison, and Graham number.
ACCE opinionConcentra Group Holdings Parent Inc. Common Stock (CON)
Fair value (3 models)
$26.63
ACCE price target
$37.50
Rating
Overvalued
Horizon
12 months
Fair value published on 21 Oct 2026, 13:04 CEST; previously $35.22 since 17 Oct 2026, 00:00 CEST.
ACCE price target published on 11 Oct 2026, 00:00 CEST.
Rating published on 21 Oct 2026, 13:04 CEST.
Price used: $39.25 at the close on 23 Oct 2026, 22:00 CEST.
Models: Discounted cash flow, P/E comparison, and EV/EBITDA comparison.
Fair value: the average of the applicable valuation models (discounted cash flow, multiples, residual income, dividend discount, shareholder yield), each run on the latest financial statements and the market price shown. Opinion columns (fair value, target, rating) are shown apart from the data. Full methodology: acceinvestments.com/data/how-we-value-stocks
Full methodology
Conflicts of interest: The author holds no personal position in this security. General statement
Produced by ACCE Investments (acceinvestments.com)
Data
Price vs fair value
47.4% above
-32.2% to fair value
ACCE score
74
out of 100
Analysts
100% buy
9 covering
P/E
25.3x
forward 21.3x
1-year return
+91.0%
Dividend yield
0.63%

Concentra Group Holdings Parent Inc. Common Stock in four questions

Plain answers, details below
Free accounts get 5 full stock pages a month, including the four answers.
OverviewAsk ACCEValuationQualityAnalystsSmart MoneyCompareNews and Record

Overview

ACCE thesis

Concentra Group runs occupational health clinics, where it treats work-related injuries, performs physicals and drug screens, and provides medical services for employers, mostly under contract with workers' compensation carriers and self-insured employers. The moat is scale and density: it operates a large clinic network across many U.S. markets, and its contracted referral relationships with employers and carriers are hard to replicate one location at a time. Revenue growth of 10.0% is paired with a 19.3% operating margin and a 47.1% return on equity, which points to a business that is both expanding and converting that growth into profit. The forward P/E of 18.0 sits well below the trailing 24.2, so the market is pricing in earnings growth over the next year rather than paying for what has already been reported. For a concentrated book, the question is whether that earnings step-up holds up, and the reported numbers are a reasonable place to start that check.

AI-assisted·How I use AIWritten Oct 18, 2026
⚠ Investor warnings · 3 flagsAI-assisted·How I use AI
  • high
    Heavy leverage
    Debt/Equity of 5.35 leaves little balance-sheet room if operations weaken, even with $197M of free cash flow.
  • moderate
    Insider selling, no buying
    Insiders disclosed $14.60M in sales across the last 10 filings and no purchases, a pattern worth noting against a 9.6% insider stake.
  • moderate
    Valuation stretched vs model
    The price trades 47.4% above the model fair value of $26.63, and 4.7% above the ACCE price target of $37.50.

AI research notes

AI-assisted·How I use AIWritten Oct 21, 2026 · figures from 2026-06-30 · prices to Oct 23, 2026
Why it could do well
  • Free cash flow over the last twelve months reached $197M, a sizeable cash engine for a company of this scale.
  • Revenue grew 10.0% year over year, ahead of its 5.7% average annual pace over five years.
  • Nine of nine covering analysts rate the stock Buy or Strong Buy, and their mean target sits 7.5% above the current price.
Why it could disappoint
  • The stock trades 47.4% above the model fair value of $26.63, and three of four valuation models point there.
  • Debt is 5.35 times equity, a heavy load that leaves little room if fee schedule cuts squeeze earnings.
  • Return on invested capital is only 5.5%, far below the 47.1% return on equity, so most of the equity gain comes from borrowed money.
Each chip shows the exact figure and where it comes from. A claim without a source is not published.

Next results

Nov 5, 2026
We update the fair value about 2 days after the results, once the new figures are filed.Add to calendarGoogle

Walk me through this stock

Plain-English pros, cons, and what to watch. Pro feature.

PRO

Ask ACCE

Valuation

INVESTOR
Where CON's valuation models land
Price
$39.25
Model fair value
$26.63
Model range
$19.05 to $40.45
Fair value $26.63
Price $39.25
The price sits inside the model range.
Model
Fair value
Upside
Discounted cash flow
EV/EBITDA comparison
Graham number
P/E comparison
Create a free account: 5 full stock pages a month, no card.

See what each model says, the assumptions behind it, the bad, normal and good cases, and why the fair value changed.

Quality

INVESTOR
Quality and conviction INVESTOR FEATURE

The full quality picture: a reason under every score, how the scores moved, and the conviction breakdown.

  • +A plain reason under every score
  • +Conviction breakdown and growth / value / quality / momentum scores
  • +Score history: how each score moved over time

Analysts

Wall Street consensus

Bullish100% buy · 9 covering analysts
● Strong buy 7● Buy 2● Hold 0● Sell 0● Strong sell 0
Analyst intelligence INVESTOR FEATURE

The full analyst picture: the price-target distribution against the current price, forward consensus estimates, and how ACCE's own models compare.

  • +Price-target low / average / high vs the current price, with implied upside
  • +Forward revenue and EPS consensus by fiscal year
  • +ACCE fair-value models lined up against the Street

Smart Money

PRO

In one line

Trades are only made public after a delay. We show the delay so you know how old the news is.

Company insiders
No trades filed
Last 90 days
Congress
No trades filed
Last 180 days
Average delay
No trades filed
From trade to public filing
Do politicians beat the market? Our backtest →
Smart money tracking PRO FEATURE

Follow the informed money: 13F position changes, insider and Congress trades, and 13D activist filings.

  • +Quarter-over-quarter institutional position changes
  • +Every insider and Congress trade, with how late it was disclosed
  • +Active 13D activist filings and top holders

Compare

Where it sits vs peers

News and Record

Press releases mentioning this company

Recent performance

1 week
+1.8%
1 month
+12.8%
3 months
+24.2%
6 months
+72.0%
YTD
+99.4%
1 year
+91.0%

SEC filings

Recommendation history, last 12 months

DateTypeNewPreviousPrice
21 Oct 2026, 13:04 CESTRatingOvervaluedfirst publication$38.76
21 Oct 2026, 13:04 CESTFair value$26.63$35.22$38.76
17 Oct 2026, 00:00 CESTFair value$35.22$40.18$39.15
12 Oct 2026, 00:00 CESTFair value$40.18$39.21$37.19
11 Oct 2026, 00:00 CESTACCE price target$37.50first publication$37.19
28 Sept 2026, 00:00 CESTFair value$39.21$39.89$35.01
20 Sept 2026, 00:00 CESTFair value$39.89$40.39$35.47
17 Sept 2026, 00:00 CESTFair value$40.39$39.90$35.62
14 Sept 2026, 00:00 CESTFair value$39.90$40.57$34.95
12 Sept 2026, 00:00 CESTFair value$40.57$41.11$34.24

This analysis is not personalised investment advice and does not take your situation, objectives or risk tolerance into account. ACCE Investments is not an authorised investment firm.

Investing in shares carries a risk of losing capital. The value of an investment can go down as well as up.

Valuation horizon: 12 months from the publication date.

Conflicts of interest. ACCE Investments is operated by Adrien Chantreuil, who may hold personal positions in the securities analysed. Positions are declared on each security. ACCE receives no payment from the companies analysed or from any intermediary for this analysis.

Get the full CON page, free

Every model, the scenarios, fair value history, AI notes and the four questions. 5 full stock pages every month on the free plan, no card.

Free accounts get 5 full stock pages a month, including the full page.

Snapshot

Growth76Value58Quality64Momentum97Total74
Valuation
Trailing P/E
25.3x
Forward P/E
21.3x
PEG
0.54
P/B
9.30x
EV / Revenue
2.8x
Book value/sh
$3.74
Enterprise value
$6.4B
Profitability
ROE
47.1%
FCF yield
3.87%
ROIC
5.5%
Health and risk
Debt / equity
5.35
Dividend yield
0.63%
Beta
0.63

Price

+87.7% · 1Y

Ask anything about CON

Answered from Concentra Group Holdings Parent Inc. Common Stock fundamentals + recent valuations. Every number shows its source and date.

This stock Peer Peer median weaker → stronger
P/Ebetter than 83% of peers
low 23.7x25.3xhigh 104.5x
ROEbetter than 100% of peers
low 3%47%high 47%
Div yieldbetter than 83% of peers
low 0.0%0.6%high 0.8%

Peers

Prices Oct 23, 2026
CompanyPriceFair valuevs fair valueP/EROEQualityScore
CON Concentra Group Holdings Parent Inc. Common Stock$39.25$2747% above25.3x47.1%6474
LFST LifeStance Health Group Inc. Common Stock$12.56$697% above99.5x3.4%5165
OPCH Option Care Health Inc. Common Stock$31.29$4632% below23.7x16.0%4858
FORTIS.NS Fortis Healthcare Limited₹726.65--51.4x-7645
ASTERDM.NS Aster DM Quality Care Limited₹654.70--104.5x-7144
MCOV-B.ST Medicover AB (publ)kr 270.00kr 17654% above45.2x15.5%4354
CHE Chemed Corp$520.15$38934% above25.8x27.1%7876

Sector report card

Where CON ranks against its sector peers on each metric.

Computing percentiles…
  • Business Wire•Oct 8, 2026
    Concentra to Announce Third Quarter 2026 Results on Thursday, November 5, 2026
  • PR Newswire•Sep 15, 2026
    EQ's Concentra awards $150,000 to credit unions strengthening Canadian communities
  • Business Wire•Sep 14, 2026
    Concentra Expands Florida Footprint with New Daytona Beach Medical Center
5 more press releases · full archive on Investor+.INVESTOR
39 filings
September 2026
Sep 8
8-KCurrent reportPeriod 2026-09-04
View on SEC →
August 2026
Aug 27
8-KCurrent reportPeriod 2026-08-21
View on SEC →
Aug 25
Form 4Insider transactionPeriod 2026-08-21
View on SEC →
36 more filings + AI summaries on Investor+.INVESTOR